Core Viewpoint - NeurAxis, Inc. reported strong financial growth in Q1 2025, with a 39% year-over-year revenue increase, driven by expanding treatment access and positive payer coverage for its neuromodulation therapies [4][7]. Financial Highlights - Revenues for Q1 2025 reached $896 thousand, up from $647 thousand in Q1 2024, marking a 39% increase year-over-year and an 18% increase quarter-over-quarter [7][9]. - Operating loss improved by 9% when excluding a one-time legal settlement, with a reported operating loss of $2.3 million, an increase of 25% compared to $1.8 million in Q1 2024 [12][13]. - Cash balance as of March 31, 2025, was $2.0 million, with no long-term debt [14]. Operational Highlights - The company treated 300 patients in Q1 2025, indicating an annualized treatment rate of 1,200 patients, which is still a small fraction of the 600,000 children in the U.S. suffering from IBS [4][6]. - Positive coverage policies now encompass approximately 51 million lives, a significant increase from 4 million as of December 31, 2023 [5][7]. - NeurAxis received FDA clearance for expanding the IB-Stim label to include patients aged 8-21 and for its rectal expulsion device (RED), which is expected to generate meaningful revenues starting in Q2 2025 [7][8]. Management Commentary - The CEO highlighted that the growth is attributed to physicians becoming more comfortable with billing processes and increased awareness of treatment guidelines [5][6]. - The company anticipates that the upcoming publication of academic society guidelines and the implementation of a Category I CPT code on January 1, 2026, will be critical for expanding insurance coverage and driving national growth [6][9]. Market Position - NeurAxis is focused on expanding its pediatric addressable market and has submitted for FDA clearance to include pediatric Functional Dyspepsia, which could effectively double its market size [8]. - The company is committed to clinical research, with 16 peer-reviewed publications supporting its PENFS technology, enhancing its position for expanding payer coverage [7].

Core Insights - IMUNON, Inc. is advancing its lead candidate IMNN-001 in a Phase 3 clinical trial for newly diagnosed advanced ovarian cancer, with the first trial site initiated for the OVATION 3 study [5][6] - The Phase 2 OVATION 2 study data has been accepted for oral presentation at the 2025 ASCO Annual Meeting, highlighting the potential of IMNN-001 in improving patient outcomes [8][9] - The company reported a net loss of $4.1 million for Q1 2025, a decrease from $4.9 million in Q1 2024, indicating improved financial management [15][18] Recent Developments - The initiation of the first trial site for the OVATION 3 study is a significant milestone in the development of IMNN-001, which aims to provide a new treatment option for women with advanced ovarian cancer [5][6] - The OVATION 2 study demonstrated that IMNN-001, when combined with chemotherapy, is the first immunotherapy to extend both progression-free and overall survival in newly diagnosed ovarian cancer patients [3][4] - New translational data from the OVATION 2 study showed a 20% increase in IL-12 levels in patients treated with IMNN-001 compared to those receiving a lower dose, reinforcing the drug's mechanism of action [10] Financial Performance - For Q1 2025, operating expenses were reported at $4.1 million, down 18% from $5.0 million in Q1 2024, primarily due to reduced R&D costs [15][16] - Research and development expenses decreased to $2.2 million in Q1 2025 from $3.3 million in Q1 2024, reflecting lower costs associated with ongoing clinical trials [16] - As of March 31, 2025, the company had cash and cash equivalents of $2.9 million, which is expected to fund operations into late Q2 2025 [18] Clinical Trials and Research - The Phase 3 OVATION 3 trial will evaluate the safety and efficacy of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy compared to standard care [6] - The study will include women with newly diagnosed advanced ovarian cancer, focusing on overall survival as the primary endpoint [6] - Data from the OVATION 2 study will be published in the peer-reviewed journal Gynecologic Oncology, further validating the findings of the trial [7]

SINGAPORE, May 12, 2025 /PRNewswire/ -- Canaan Inc. (NASDAQ: CAN) ("Canaan" or the "Company"), an innovator in crypto mining, today announced that it plans to report its financial results for the first quarter ended March 31, 2025, before the U.S. market opens on May 20, 2025.The Company's management team will hold a conference call at 8:00 A.M. on May 20, 2025, U.S. Eastern Time (8:00 P.M. on the same day, Singapore Time) to discuss the financial results. Details for the conference call are as follows: E ...

Core Viewpoint - Vipshop Holdings Limited plans to release its first quarter 2025 financial results on May 20, 2025, before the US market opens [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call scheduled for May 20, 2025, at 7:30 am US Eastern Time and 7:30 pm Beijing Time [1] - Participants must pre-register online to join the conference call [2] - A live webcast of the earnings conference call will be available, with an archived version accessible later on the company's investor relations website [3] Group 2: Company Overview - Vipshop Holdings Limited is a leading online discount retailer for brands in China, offering high-quality branded products at significant discounts [4] - The company has rapidly built a sizeable and growing customer base and brand partnerships since its founding in August 2008 [4]

AUSTIN, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Volcon Inc. (NASDAQ: VLCN) (“Volcon'', the “Company” or “we”), the first all-electric, off-road powersports company, today reported its operational highlights and financial results for the quarter ended March 31, 2025. Company Highlights: ● Sold all remaining Grunt EVO motorcycles in Q1● Signed amended and restated golf cart supply agreement with Venom-EV● Evaluating impact of tariffs on products In the first quarter of 2025, Volcon successfully sold all re ...

MINNEAPOLIS, May 09, 2025 (GLOBE NEWSWIRE) -- Nortech Systems Incorporated (Nasdaq: NSYS) (the “Company”), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical imaging, medical device, aerospace & defense and industrial markets, will hold a live conference call and webcast at 3:30 p.m. Central Time on Wednesday May 14, 2025, to discuss the Company's first quarter 2025 financial results. The call will be hosted by Jay D. M ...

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Krispy Kreme, Inc. (“Krispy Kreme” or the “Company”) (NASDAQ: DNUT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Krispy Kreme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On ...

Core Viewpoint - Humacyte, Inc. is set to release its financial results for Q1 2025 on May 13, 2025, and will provide a corporate and financial update during a webcast and conference call [1][2]. Company Overview - Humacyte, Inc. is a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [1][3]. - The company manufactures acellular tissues aimed at treating various diseases, injuries, and chronic conditions [3]. - The FDA approved the Biologics License Application for Humacyte's acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024 [3]. - ATEVs are currently in late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [3]. - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, type 1 diabetes treatment, and other novel cell and tissue applications [3]. - Humacyte's 6mm ATEV for AV access in hemodialysis is notable for being the first product to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received Fast Track designation [3]. - The ATEV has received priority designation for vascular trauma treatment from the U.S. Secretary of Defense [3]. Financial Results Announcement - The financial results for the quarter ended March 31, 2025, will be announced on May 13, 2025, at 8:30 AM ET [2]. - A conference call will be available for U.S. and international investors, with specific dial-in numbers provided [2]. - The webcast will be accessible 15 minutes prior to the call and will be available for replay for at least 30 days [2].

Core Viewpoint - PyroGenesis Inc. is set to host a conference call on May 14, 2025, to discuss its financial results for Q1 2025 and provide updates on company progress and developments [1]. Company Overview - PyroGenesis is a high-tech company specializing in advanced all-electric plasma processes and sustainable solutions aimed at supporting heavy industries in energy transition, emission reduction, commodity security, and waste remediation [1][3]. - The company has developed proprietary and patented plasma technologies that are being adopted by major industry players in four key markets: iron ore pelletization, aluminum, waste management, and additive manufacturing [3]. - PyroGenesis operates from its Montreal office and has manufacturing facilities of 3,800 m² and 2,940 m², maintaining a competitive edge through continuous technology development and commercialization [3]. - The company is ISO 9001:2015 and AS9100D certified, having been ISO certified since 1997 [3]. - PyroGenesis' shares are publicly traded on the TSX (TSX: PYR), OTCQX (OTCQX: PYRGF), and Frankfurt Stock Exchange (FRA: 8PY1) [3].

Core Insights - Gogo Inc. reported total revenue of $230.3 million for Q1 2025, representing a 121% increase year-over-year and a 67% increase compared to Q4 2024 [3][34] - Service revenue reached $198.6 million, up 143% year-over-year, while equipment revenue was $31.7 million, a 40% increase year-over-year [3][34] - The company achieved PMA approval for its larger LEO antenna, FDX, ahead of schedule, which is expected to enhance service revenue starting in Q1 2026 [5] Financial Performance - Net income for Q1 2025 was $12.0 million, compared to $30.5 million in Q1 2024 and a net loss of $28.2 million in Q4 2024 [3][22] - Adjusted EBITDA for Q1 2025 was $62.1 million, reflecting a 43% increase year-over-year and an 83% increase compared to Q4 2024 [3][37] - Free Cash Flow for Q1 2025 was $30.0 million, down from $32.1 million in the prior-year period but up from a negative $39.6 million in Q4 2024 [9][37] Operational Metrics - Total ATG AVANCE aircraft online grew to 4,716, a 15% increase year-over-year [3][31] - Average Monthly Connectivity Service Revenue per ATG aircraft online was $3,451, remaining flat compared to Q1 2024 [3][31] - The company shipped 59 HDX antennas year-to-date, with 38 HDX Supplemental Type Certificates under contract, targeting a total addressable market of nearly 32,000 aircraft [9][9] Strategic Outlook - Gogo reiterated its 2025 financial guidance, projecting total revenue between $870 million and $910 million and adjusted EBITDA between $200 million and $220 million [6][7] - The company anticipates Free Cash Flow in the range of $60 million to $90 million for 2025, with capital expenditures of approximately $60 million [7][39] - Gogo plans to provide longer-term financial targets later in 2025, with preliminary targets indicating 10% revenue growth and adjusted EBITDA margins in the mid-20s [8]